Theravance Biopharma, Inc. (TBPH)

NASDAQ: TBPH · IEX Real-Time Price · USD
+0.08 (0.76%)
Nov 30, 2023, 12:07 PM EST - Market open

Company Description

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe.

The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD).

The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma.

It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

Theravance Biopharma, Inc.
Theravance Biopharma logo
Country Cayman Islands
Industry Biotechnology
Sector Healthcare
Employees 111
CEO Rick E. Winningham M.B.A.

Contact Details

Ugland House, South Church Street
George Town, Grand Cayman, E9 KY1-1104
Cayman Islands
Phone 650-808-6000

Stock Details

Ticker Symbol TBPH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001583107
CUSIP Number G8807B106
ISIN Number KYG8807B1068
SIC Code 2834

Key Executives

Name Position
Rick E. Winningham M.B.A. Chairman and Chief Executive Officer
Andrew Asa Hindman M.B.A Senior Vice President and Chief Financial Officer
Rhonda F. Farnum Chief Business Officer and Senior Vice President of Commercial and Medical Affairs
Dr. Richard A. Graham Ph.D. Senior Vice President of Research & Development
Gail B. Cohen Vice President of Corporate Communications and Investor Relations
Brett A. Grimaud Esq. Senior Vice President, General Counsel and Secretary
Stacy L. Pryce Senior Vice President and Chief Strategy Officer

Latest SEC Filings

Date Type Title
Nov 14, 2023 144 Filing
Nov 9, 2023 10-Q Quarterly Report
Nov 7, 2023 8-K Current Report
Oct 30, 2023 8-K Current Report
Oct 16, 2023 144 Filing
Sep 14, 2023 144 Filing
Sep 12, 2023 8-K Current Report
Aug 14, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Aug 11, 2023 144 Filing
Aug 9, 2023 10-Q Quarterly Report